We hypothesized that the concomitant targeting of both MAPK and PI3K–Akt pathways in a PIK3CA-mutated melanoma model resistant to BRAF and MEK inhibitors would result in a better therapeutic efficacy that reverts drug resistance mechanisms. The gene discussed is AKT1; the disease is melanoma.